Introduction
============

Hepatocellular carcinoma (HCC) is the sixth most common solid cancer and the third leading cause of cancer-related mortality worldwide ([@b1-ol-07-05-1430]). The occurrence of HCC is multi-factorial and it often develops under an established background of chronic liver diseases ([@b2-ol-07-05-1430]--[@b4-ol-07-05-1430]). The most outstanding risk factor in Eastern Asia is chronic hepatitis B virus (HBV) infection, while in Japan, Europe and North America, hepatitis C virus (HCV) infection is the notable risk factor, synergistically with alcohol abuse ([@b5-ol-07-05-1430]). Liver resection is potentially a curative therapy in HCC patients who are within the Milan criteria and have an adequate liver reserve. However, tumor recurrence occurs in \>50% of cases within 5 years following surgery, combining true recurrence of the original cancer, which usually arises within the first 2 years, and *de novo* tumor formation ([@b6-ol-07-05-1430]). Early recurrence is associated with microvascular invasion, poor histological differentiation, satellites and multifocal disease, while late recurrence is mainly dependent on the oncogenic potential of underlying chronic liver disease ([@b7-ol-07-05-1430],[@b8-ol-07-05-1430]). Specific molecules have been identified as factors for predicting postoperative survival. These include proline-directed protein kinase FA, mitogen-activated protein kinase phosphatase-1, vascular endothelial growth factor, proliferating cell nuclear antigen, p53, tissue factor, cytokeratin-19, telomerase activity and interleukin-10 ([@b4-ol-07-05-1430],[@b9-ol-07-05-1430]--[@b16-ol-07-05-1430]). In patients with HBV-related HCC, the HBV basal core promoter mutation and HBV-DNA level in liver tissues also predict a poor postoperative survival rate ([@b17-ol-07-05-1430]).

Oxidative phosphorylation (OXPHOS) in mitochondria provides biological energy for intracellular metabolic pathways ([@b18-ol-07-05-1430]). It is particularly significant in hepatocytes as the liver is one of the most energy-consuming organs. In 1930, Warburg proposed that cancer originated from an irreversible injury to mitochondrial OXPHOS, which forced cancer cells to shift to an energy-generation process through glycolysis despite the presence of aerobic conditions. This condition has been named as the Warburg effect ([@b19-ol-07-05-1430]). It renders cancer cells capable of surviving and proliferating under adverse conditions. Mitochondrial DNA (mtDNA) is more susceptible to oxidative damage and has a higher mutation rate than nuclear DNA due to a lack of protective histones, limited DNA repair activities and a proximity to the high rate of reactive oxygen species generated in mitochondria ([@b20-ol-07-05-1430]--[@b22-ol-07-05-1430]). As such, the accumulation of mtDNA alterations in cancer cells leading to defects in adenosine triphosphate (ATP) generation through the OXPHOS system is consistent with the theory of the Warburg effect. Mutations in mtDNA have been reported in various types of human cancers ([@b23-ol-07-05-1430]--[@b25-ol-07-05-1430]). These findings indicate that defects of the OXPHOS complex with mitochondrial-encoded subunits may be a decisive factor in hepatocarcinogenesis.

The OXPHOS process consists of five complexes, which are complex I (NADH: ubiquinone oxidoreductase), complex II (succinate dehydrogenase), complex III (cytochrome *bc*1 complex), complex IV (cytochrome *c* oxidase) and complex V (ATP synthase), and all are localized on the inner mitochondrial membrane. During electron transport, complexes I, III and IV pump protons from the mitochondrial matrix to the inter-membrane space, resulting in an increase in the membrane potential across the inner mitochondrial membrane. Following this, complex V actively allows the flow of protons back to the matrix, resulting in the generation of energy in the form of ATP from adenosine diphosphate ([@b26-ol-07-05-1430]). The OXPHOS system consists of 85 subunits as components of various complexes, in which 13 are encoded in mtDNA. These 13 mitochondrial-encoded proteins constitute various subunits that make up four OXPHOS complexes (complex I, III, IV and V) ([@b27-ol-07-05-1430]). Studies have demonstrated that the mtDNA mutations alter the mitochondrial-encoded subunits and play a significant role in numerous malignancies, including renal oncocytoma, thyroid oncocytic carcinoma, bladder, prostate and colon cancer ([@b28-ol-07-05-1430]--[@b32-ol-07-05-1430]).

MtDNA mutations have also been identified in HCC ([@b33-ol-07-05-1430]--[@b35-ol-07-05-1430]). These mutations potentially cause the defects of mitochondrial-encoded subunits in the OXPHOS system and result in mitochondrial dysfunction in HCC ([@b36-ol-07-05-1430]). It has been demonstrated that the defects of complexes III and IV can be detected by immunohistochemical (IHC) staining in normal human and cirrhotic liver during aging. However, these defects were not shown in 27 sections of HCC tissues ([@b37-ol-07-05-1430]). The actual defects of mitochondrial-encoded subunits in HCC and the association with the outcome remain unclear. The present study aimed to examine the expression of the defects of the mitochondrial-encoded OXPHOS subunits; complex I subunit 6 (CI-6), complex III subunit 3 (CIII-3), complex IV subunit 1 (CIV-1) and complex V subunit 6 (CV-6), in surgically removed HCCs, and their correlations with clinicopathological factors and prognosis.

Patients and methods
====================

Patients and specimens
----------------------

Under the approval of the Institutional Review Board, Chang Gung Medical Center (Taoyuan, Taiwan), 102 human HCC tissues with a clear surgical margin were randomly collected from patients undergoing curative resection at Chang Gung Memorial Hospital at Linkou (Taoyuan, Taiwan) between 1996 and 2006 and stored in the Chang Gung tissue bank. The tissues were retrieved from the tissue bank and formalin-fixed and paraffin-embedded for the IHC study. The inclusion criteria included pathological diagnosis of HCC, no anticancer therapy prior to the surgery, curative resection, adequately formalin-fixed and paraffin-embedded tissues, complete clinicopathological data, regular follow-up and reliable medical records. The exclusion criteria included pregnancy, other co-existing malignancies and mortality due to unrelated diseases.

The clinical parameters included age, gender, chronic HBV, chronic HCV, liver cirrhosis, ascites, α-fetoprotein (AFP), albumin, bilirubin, prothrombin time, creatinine, aspartate aminotransferase (AST), alanine aminotranferease (ALT), alcohol use (average alcohol consumption of \>210 g per week in males or \>140 per week in females over at least a 2-year period), local recurrence, time to local recurrence, distant metastasis, time to distant metastasis, mortality and overall survival time. The pathological findings, including tumor grade, microvascular invasion, macrovascular invasion, capsule, tumor number and largest tumor diameter, were examined by two experienced pathologists without information of the clinical data.

Curative resection was defined as a complete resection of all tumors with the margin free from cancer invasion by histological examination, no tumor thrombus in the main trunk, two major portal branches, hepatic veins or bile duct and no extrahepatic metastasis ([@b38-ol-07-05-1430]). HCC diagnosis and grading were established according to World Health Organization criteria ([@b39-ol-07-05-1430]). Macrovascular invasion was defined as the invasion of the tumor into the vessels that can be identified during macroscopic examination or radiological imaging. The definition of microvascular invasion included: i) Presence of tumor cells forming a plug or polyp in a subendothelial location, partially or totally covered by endothelial cells; ii) presence of tumor thrombus, partially or totally covered by the endothelium; iii) vascular structures involved can be portal vein branches, hepatic vein branches or capsule vessels, inside the tumor or closely situated to the tumor edge; and iv) invasion of arteries and lymphatic vessels ([@b40-ol-07-05-1430]). Local recurrence was defined as intrahepatic recurrence and distant metastasis was equal to extrahepatic metastasis.

Ethics statement
----------------

This study was approved by Chang Gung Medical Foundation Institutional Review Board (no. 100-1728B, between 01/08/2011 and 31/07/2014; Taoyuan, Taiwan). The Institutional Review Board waived the requirement for informed consent from the participants as the present study was a retrospectively observational analysis and the information identifying patients was not included in the collected data. Tissue samples were obtained from the Tissue Bank of Linkou Chang Gung Memorial Hospital (Taoyuan, Taiwan) through approval of the committee.

IHC analysis
------------

The IHC stains were performed for detection of the expression defects of CI-6, CIII-3, CIV-1 and CV-6 with rabbit anti-nicotinamide adenine dinucleotide (NADH) dehydrogenase subunit 6 polyclonal antibody (Abcam, Cambridge, MA, USA), goat anti-cytochrome *b* polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), mouse anti-OXPHOS complex IV subunit I monoclonal antibody (Invitrogen Life Technologies, Carlsbad, CA, USA) and rabbit anti-mt-ATP6 polyclonal antibody (Abcam), respectively. Deparaffinized rehydrated sections were treated with H~2~O~2~ (3% in distilled water) for 15 min, pre-incubated with normal serum (goat serum for rabbit anti-NADH dehydrogenase subunit 6 antibody and anti-mt-ATP6 antibody; horse serum for anti-OXPHOS complex IV subunit I monoclonal antibody; and rabbit serum for anti-cytochrome *b*) with phosphate-buffered saline in the proportion of 1:10 for 40 min. Following this, the sections were then incubated with the specific primary antibody (1 h at 37°C for anti-NADH dehydrogenase subunit 6 antibody and anti-OXPHOS complex IV subunit I monoclonal antibody; and overnight at 4°C for anti-cytochrome *b* and anti-mt-ATP6 antibody) and the secondary antibody of the VECTASTIN Elite ABC kit \[anti-rabbit immunoglobulin G (IgG) for rabbit anti-NADH dehydrogenase subunit 6 antibody and anti-mt-ATP6 antibody; anti-mouse IgG for anti-OXPHOS complex IV subunit I monoclonal antibody; and anti-goat IgG for anti-cytochrome *b*; Vector Laboratories, Inc., Burlingame, CA, USA\] for 40 min at room temperature. Visualization was performed with the 3,3′-diaminobenzidine substrate kit, SK-4100 (Vector Laboratories, Inc.). The stained sections were examined separately by two experienced pathologists, who were blinded to the clinical information. The defect areas (absence of reactivity) in the tumor were estimated and recorded as percentages. If there was a discrepancy in the interpretation, a consensus was reached between the two pathologists by reviewing slides simultaneously. Tissues were classified into two groups based on the percentages of the defect areas in a single cross-section of the HCC samples (major defect, \>25% HCC area; and minor defect, ≤25% of the HCC area) for further evaluation.

Statistical analysis
--------------------

Numerical data are presented as mean ± standard deviation, while categorical data were expressed as absolute number and percentages. The χ^2^ test was used for group comparisons involving binary data and independent samples. Mann-Whitney U test was used for the largest tumor size, AFP, AST, ALT, local recurrent time, distal metastatic time and disease-free survival time, due to a skewed distribution. Other numerical data were evaluated by Student's t-test. The results were considered to indicate a statistically significant difference when P\<0.05. Univariate and multivariate analyses were performed by Cox proportional hazards regression to identify independent risk factors for mortality. The results were presented with hazard ratio (HR), 95% confidence interval (CI) and P*-*value. Survival curves were also analyzed by the Kaplan-Meier curve and log-rank test. All statistical calculations were performed using SPSS, 18.0 software (SPSS, Inc., Chicago, IL, USA).

Results
=======

Patient characteristics
-----------------------

The age of the patients at the time of surgery ranged between 25 and 89 years, and the male to female ratio was 3.64. The tumor-node-metastasis stage was between stages I and IIIA, according to the American Joint Committee on Cancer Cancer Staging Manual, seventh edition (2010) ([@b41-ol-07-05-1430]). The cohort of the present study included 51 liver cirrhosis patients, 38 alcohol users, 70 chronic HBV carriers, 17 chronic HCV carriers and 3 HBV and HCV co-infection patients. The average follow-up duration was 50.29±43.50 months. The rates of mortality, local recurrence, distal metastasis, 5-year survival and 5-year disease-free survival were 36.27, 64.71, 39.22, 37.25 and 22.55%, respectively.

Clinicopathological characteristics
-----------------------------------

The majority of the HCC tissues contained various degrees of mitochondrial-encoded OXPHOS enzyme defects. The expression defects of CI-6, CIII-3, CIV-1 and CV-6 were present in 100, 98, 98 and 93% of the tissues assessed, respectively. The major and minor defects were defined as IHC staining defect area of \>25% and ≤25%, respectively ([Fig. 1](#f1-ol-07-05-1430){ref-type="fig"}). According to this definition, the frequency of the major defect for CI-6, CIV-1, CIII-3 and CV-6 was 67.7, 50.0, 31.3 and 24.5%, respectively. The CI-6 major-defect group had lower ALT levels compared with the minor-defect group \[35 (10-280) and 59 (9-371) U/l, P=0.038\]. The CIII-3 major-defect group had fewer encapsulated tumors (56.25 and 75.71%, P=0.047) and higher albumin levels (4.03±0.44 and 3.67±0.68 g/dl, P=0.002), compared with the minor-defect group. The CIV-1 major-defect group had higher AFP levels \[204.08 (0.9-89637.7) and 21.92 (2-286980) ng/ml, P=0.021\] and higher AST levels \[63 (12-351) and 36 (11-278) U/l, P=0.018\] compared with the minor-defect group. The CV-6 major-defect group was older (63.12±9.80 and 53.86±15.53 years, P=0.001) compared with the minor-defect group. There was no other significant difference in clinicopathological parameters between the major- and minor-defect groups ([Table I](#tI-ol-07-05-1430){ref-type="table"}).

Clinicopathological parameters and OXPHOS expression defects associated with post-operative survival in HCC
-----------------------------------------------------------------------------------------------------------

Univariate analysis revealed that ascites (HR, 6.016; 95% CI, 2.364--15.309; P\<0.001), albumin levels (HR, 0.524; 95% CI, 0.304--0.905; P=0.020), time to local recurrence (HR, 0.948; 95% CI, 0.927--0.970, P\<0.001), time to distant metastasis (HR, 0.934; 95% CI, 0.915--0.953; P\<0.001), disease-free survival time (HR, 0.948; 95% CI, 0.927--0.969; P\<0.001) and major CIV-1 defect (HR, 3.050; 95% CI, 1.471--6.324; P=0.003) were associated with the overall survival time ([Table II](#tII-ol-07-05-1430){ref-type="table"}). These six factors were further analyzed by multivariate analysis. It was found that the major CIV-1 defect (HR, 5.676; 95% CI, 2.243--14.360; P\<0.001) and the time to distant metastasis (HR, 0.924; 95% CI, 0.894--0.955; P\<0.001) were significant independent predictive factors for overall survival time ([Table III](#tIII-ol-07-05-1430){ref-type="table"}). Kaplan-Meier survival analysis using the log-rank test ([Fig. 2](#f2-ol-07-05-1430){ref-type="fig"}) also showed that the CIV-1 major-defect group had an unfavorable survival time compared with that of the minor-defect group (P=0.002). Additionally, the major CI-6 and CV-6 defect groups appeared to have a poor survival rate within 8 years, but it did not reach statistical significance. There was no significant difference between major- and minor-defect groups of CIII-3, according to the Kaplan-Meier survival curve.

Discussion
==========

According to the present study, the majority of the HCC tissues contained various degrees of mitochondrial-encoded OXPHOS complex defects, indicating the impairment of ATP production by pyruvate oxidation in mitochondria. This result is compatible with the phenomenon of the Warburg effect, indicating that energy is mainly supplied by glycolysis in cancer cells ([@b19-ol-07-05-1430]). To understand whether the degree of OXPHOS defects correlate with clinicopathological presentation and prognosis, the major and minor defects were defined as IHC staining defect area of \>25% (major) and ≤25% (minor). The frequencies of the major defect were as follows: CI-6, 67.65%; CIV-1, 50.00%; CIII-3, 31.37%; and CV-6, 24.51%). These results indicate that HCC tissues tend to have a larger portion of CI-6 and CIV-1 defects, rather than CIII-3 and CV-6. It has been indicated that the OXPHOS enzyme defects are associated with aging ([@b37-ol-07-05-1430]). However, in the present study, only the major CV-6 defect was correlated with age (63.12±9.80 and 53.86±15.53 years, P=0.001), indicating that other mechanisms are responsible for the generation of these defects in HCC, rather than aging. Through univariate and multivariate analyses, the major CIV-1 defect was found to be a negative predictive factor for HCC patients following curative resection.

Complex IV is the terminal oxidase of the respiratory chain in the mitochondria. In mammals, it contains 13 subunits, of which 3 catalytic subunits (subunit 1, 2 and 3) are encoded by the mitochondrial genes. The remaining 10 subunits are encoded by nuclear DNA and are suspected to be involved in the regulation and/or assembly of the complex ([@b41-ol-07-05-1430]). Complex IV represents the rate-limiting enzyme of the mitochondrial respiratory chain and its activity is an indicator of the oxidative capacity of the cells. It is therefore fated to be a central site of regulation of oxidative phosphorylation, proton pumping efficiency, ATP and reactive oxygen species production, which in turn affect cell signaling and survival ([@b42-ol-07-05-1430],[@b43-ol-07-05-1430]). Complex IV can also be incorporated into larger structures containing complex I, II and III, and the mobile electron carriers, cytochrome *c* and ubiquinol, to form functional supercomplexes; respirasomes ([@b44-ol-07-05-1430],[@b45-ol-07-05-1430]). These supercomplexes may stabilize the individual complexes ([@b46-ol-07-05-1430]) to enhance respiration due to coordinated channeling of electrons ([@b47-ol-07-05-1430]). Due to the significance of complex IV, organisms have evolved various levels of regulation for its activity. A defect of complex IV has been proved to result in numerous diseases, including Leber hereditary optic neuropathy, Leigh syndrome, recurrent myoglobinuria mitochondrial disorder, deafness sensorineural mitochondrial disorder and colorectal cancer ([@b48-ol-07-05-1430]--[@b54-ol-07-05-1430]). However, their roles in HCC are not clear. The present study firstly revealed the potential significance of the CIV-I defects in HCC. Further experiments involving knocking out the CIV-I gene by small hairpin RNA in the Huh7 HCC cell line will be performed to demonstrate their effects on liver tumor.

It has been demonstrated that OXPHOS protein defects can be found in normal and cirrhotic human liver. A study by Müller-Höcker *et al* ([@b37-ol-07-05-1430]) enrolled 107 normal livers (including 11 HCC cases) and 64 cirrhotic livers (including 16 HCC cases) and aimed to detect the respiratory chain protein (complex II, III and IV) and complex V defects in normal and cirrhotic liver during aging. Enzyme histochemistry was performed to detect complex II, IV and V, and immunohistochemistry with polyclonal antibody (against both nuclear and mitochondrial subunits) was conducted for detection of total complex III and complex IV subunits 2, 3 and 4. In normal livers, the respiratory chain defects were detected in 57% cases, and 87% in advanced age (\>50 years old). In cirrhotic liver, the overall frequency of defects was higher (78%) compared with normal liver, but was inverse (60%) in advanced age. However, there were no defects of complex II, III, IV and V observed in 27 HCC tissues in their study. On the contrary, the present study showed that the majority of resected HCC tissues contain various degrees of mitochondrial-encoded subunits defects. The conflicting results may be due to the varied HCC tissue origins (metastatic and primary), various OXPHOS enzymes examined and different methods performed. Nevertheless, the results of the present study firstly demonstrated that the majority of HCCs contain mitochondrial-encoded subunit defects, indicating a potential role of these defects in hepatocarcinogenesis.

MtDNA mutations have been detected in HCC. A study by Lee *et al* ([@b33-ol-07-05-1430]) examined the D-loop mutations and mtDNA numbers in 61 HCCs and the corresponding non-tumor sections. The results showed that 39.3% of HCCs carried somatic mutations in the D-loop of mtDNA. A significant decrease in the copy number of mtDNA was also detected in 60.5% of patients with HCC ([@b33-ol-07-05-1430]). A small-scale study examining 18 HCC patients also demonstrated a significant decrease of mtDNA copy number, particularly in females but not in males with HCC ([@b34-ol-07-05-1430]). Another study examined 44 HCCs and in total 13 somatic mtDNA mutations were found in 11 HCC samples ([@b35-ol-07-05-1430]). Among these mutations, the T6768C (CIV-1), G7976A (complex IV subunit II), G9267 (complex IV subunit 3) and A111708 (complex I subunit 4) mutations could result in amino acid substitutions in the highly conserved regions and have the potential to cause mitochondrial dysfunction in HCC. Although the mutation of mtDNA was not examined in the present study, the mitochondrial-encoded OXPHOS subunit defects shown may have at least partially resulted from mtDNA mutations and the decrease of mtDNA copy number.

There were limitations in the present study regarding the case number, the choice of specimens and the lack of western blotting, reverse transcription polymerase chain reaction and mtDNA analysis. In total, 102 HCC tissues were collected with an average follow-up duration of 50.29 months (range, 0.07--194 months). The case number appeared to not be enough for subgroup analyses. Due to the strength of the IHC staining, it was more difficult to evaluate objectively and it was not associated with prognosis (data not shown); the percentages of IHC stain defect areas were chosen in a single cross-section of HCC without significant necrosis to evaluate the degree of the OXPHOS complex defects. The same scoring system read by the pathologists is also widely used in clinical practice, including HER2 in breast cancer and Ki-67 in neuroendocrine tumor ([@b55-ol-07-05-1430],[@b56-ol-07-05-1430]). Although it was easy for clinical applications, it may have bias between different pathologists when scoring the defects areas. We hypothesize that this bias can be reduced by repeated reading and experienced examiners.

To the best of our knowledge, the present study was the first to demonstrate the correlation between OXPHOS subunit defects and overall survival time in HCC patients. The results showed that the majority of HCCs contained mitochondrial-encoded OXPHOS subunit defects. Among these, the major CIV-1 defect was a negative predictor for post-operative survival in HCC. It may provide a simple way to predict the outcome in this group of patients.

This study was supported by the grants from the National Science Council (NSC100-2314-B-182A-056) and Chang Gung Medical Research Council (CMRPG3A0921), Taiwan, Republic of China.
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###### 

Correlation between CI-6, CIII-3, CIV-1 and CV-6 and clinicopathological characteristics in 102 human HCC tissues.

                                      CI-6 defect      CIII-3 defect     CIV-1 defect                                         CV-6 defect                                                                                                                                                                                                                          
  ----------------------------------- ---------------- ----------------- ---------------------------------------------------- -------------------- --------------------- ---------------------------------------------------- ------------------ ---------------------- ---------------------------------------------------- --------------------- --------------- ----------------------------------------------------
  Case number, n (%)                  33 (32.35)       69 (67.65)                                                             70 (68.63)           32 (31.37)                                                                 51 (50)            51 (50)                                                                     77 (75.49)            25 (24.51)      
  Gender, n (M/F)                     23/10            57/12             0.138                                                53/17                27/5                  0.324                                                42/9               38/13                  0.336                                                58/19                 22/3            0.181
  Age, years                          58.48±14.22      55.00±15.10       0.269                                                57.90±15.64          52.25±12.27           0.052                                                55.63±16.30        56.63±13.37            0.736                                                53.86±15.53           63.12±9.80      0.001[a](#tfn1-ol-07-05-1430){ref-type="table-fn"}
  HBsAg, n (%)                        21 (63.64)       52 (75.36)        0.219                                                47 (67.14)           26 (81.25)            0.143                                                35 (68.63)         38 (74.51)             0.510                                                57 (74.03)            16 (64.00)      0.334
  HCV, n (%)                          9 (27.27)        11 (15.94)        0.178                                                15 (21.43)           5 (15.63)             0.493                                                7 (13.73)          13 (25.49)             0.135                                                14 (18.18)            6 (24.00)       0.524
  Liver cirrhosis, n (%)              16 (48.48)       35 (50.72)        0.832                                                37 (52.86)           14 (43.75)            0.393                                                23 (45.10)         28 (54.90)             0.322                                                37 (48.05)            14 (56.00)      0.490
  Tumor grade                         2.50±0.70        2.42±0.61         0.547                                                2.47±0.66            2.38±0.60             0.535                                                2.48±0.66          2.41±0.62              0.582                                                2.47±0.62             2.36±0.70       0.449
  Microvascular invasion, n (%)       12 (36.36)       25 (36.23)        0.990                                                23 (32.86)           14 (43.75)            0.288                                                19 (37.25)         18 (35.29)             0.837                                                32 (41.56)            5 (20.00)       0.051
  Macrovascular invasion, n (%)       4 (12.12)        3 (4.35)          0.146                                                5 (7.14)             2 (6.25)              0.869                                                1 (1.96)           6 (11.76)              0.050                                                7 (9.09)              0 (0.00)        0.118
  Capsule, n (%)                      25 (75.76)       46 (66.67)        0.350                                                53 (75.71)           18(56.25)             0.047[a](#tfn1-ol-07-05-1430){ref-type="table-fn"}   33 (64.71)         38 (74.51)             0.282                                                53 (68.83)            18 (72.00)      0.765
  Tumor number                        1.58±0.97        1.59±0.85         0.922                                                1.46±0.74            1.88±1.10             0.057                                                1.55±0.86          1.63±0.92              0.656                                                1.55±0.82             1.72±1.06       0.393
  Largest tumor size (diameter, cm)   5.3 (2--20)      5 (1--77.5)       0.429                                                5 (1--20)            6.5 (2--77.5)         0.323                                                4.8 (1.8--20.5)    6 (1--77.5)            0.254                                                5.5 (2--20.5)         4 (1--77.5)     0.190
  Ascites, n (%)                      3 (9.09)         6 (8.70)          0.911                                                8 (11.43)            1 (3.13)              0.165                                                3 (5.88)           6 (11.76)              0.309                                                7 (9.09)              2 (8.00)        0.854
  AFP, ng/ml                          38 (2-44890.2)   59 (0.9-286980)   0.468                                                35.5 (1.47-286980)   133.5 (0.9-89637.7)   0.070                                                21.92 (2-286980)   204.08 (0.9-89637.7)   0.021[a](#tfn1-ol-07-05-1430){ref-type="table-fn"}   50.22 (1.47-286980)   61 (0.9-4585)   0.531
  Albumin, g/dl                       3.70±0.63        3.83±0.64         0.356                                                3.67±0.68            4.03±0.44             0.002[a](#tfn1-ol-07-05-1430){ref-type="table-fn"}   3.87±0.62          3.70±0.65              0.201                                                3.76±0.67             3.85±0.50       0.564
  Billirubin, mg/dl                   0.98±0.48        1.04±0.92         0.736                                                1.10±0.92            0.85±0.38             0.153                                                0.91±0.42          1.13±1.04              0.170                                                1.04±0.90             0.98±0.36       0.750
  Prothrombin time, sec               12.4±1.13        12.55±1.67        0.651                                                12.65±1.67           12.15±1.01            0.125                                                12.44±1.78         12.55±1.20             0.722                                                12.61±1.61            12.18±1.13      0.220
  Creatinine, mg/dl                   1.22±0.76        1.25±1.26         0.911                                                1.24±0.95            1.25±1.45             0.963                                                1.15±0.61          1.325±1.47             0.439                                                1.10±0.52             1.68±2.04       0.172
  AST, U/l                            52 (11-278)      36 (12-351)       0.520                                                40.5 (11-351)        39 (15-312)           0.908                                                36 (11-278)        63 (12-351)            0.018[a](#tfn1-ol-07-05-1430){ref-type="table-fn"}   45 (11-351)           35 (12-260)     0.361
  ALT, U/l                            59 (9-371)       35 (10-280)       0.038[a](#tfn1-ol-07-05-1430){ref-type="table-fn"}   41.5 (9-371)         41.5 (13-280)         0.905                                                40 (9-371)         47 (13-280)            0.322                                                45 (9-371)            33 (13-279)     0.800
  Alcohol use, n (%)                  14 (42.42)       24 (34.78)        0.455                                                26 (37.14)           12 (37.50)            0.972                                                15 (29.41)         23 (45.10)             0.101                                                28 (36.36)            10 (40.00)      0.744

P\<0.05. Largest tumor size, AFP, AST and ALT are presented by median (range). The remaining data are presented as the mean ± standard deviation, unless stated otherwise. AFP, α-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotranferase; CI-6, complex I subunit 6; CIII-3, complex III subunit 3; CIV-1, complex IV subunit 1; CV-6, complex V subunit 6; F, female; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; M, male; minor, immunohistochemical-negative area ≤25%; major, immunohistochemical-negative area \>25%.

###### 

Univariate analysis of parameters associated with overall survival time.

  Parameter                            Patient data                                                      SE      HR      95% CI          P-value
  ------------------------------------ ----------------------------------------------------------------- ------- ------- --------------- ------------------------------------------------------
  Gender, male                         80 (78.4%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.384   0.964   0.454\~2.046    0.924
  Age, years                           56.13±14.84                                                       0.011   1.012   0.990--1.034    0.292
  HBsAg                                73 (71.6%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.391   0.999   0.464\~2.150    0.999
  HCV                                  20 (19.6%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.485   0.727   0.281\~1.879    0.511
  Liver cirrhosis                      51 (50.0%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.332   0.919   0.479\~1.762    0.798
  Tumor grade                          2.44±0.64                                                         0.255   1.001   0.608--1.649    0.996
  Microvascular invasion               37 (36.3%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.366   1.181   0.577\~2.418    0.649
  Macrovascular invasion               7 (6.9%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}             0.535   1.799   0.630\~5.139    0.273
  Capsule                              71 (69.6%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.386   1.272   0.597\~2.709    0.533
  Tumor number                         1.59±0.88                                                         0.181   1.136   0.797--1.619    0.481
  Largest tumor size (diameter, cm)    5.1 (1.0--77.5)[b](#tfn3-ol-07-05-1430){ref-type="table-fn"}      0.012   1.012   0.989--1.037    0.313
  Ascites                              9 (8.8%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}             0.477   6.016   2.364\~15.309   \<0.001[c](#tfn4-ol-07-05-1430){ref-type="table-fn"}
  AFP (ng/ml)                          50.26 (0.9-286980)[b](#tfn3-ol-07-05-1430){ref-type="table-fn"}   0.000   1.000   1.000\~1.000    0.585
  Albumin (g/dl)                       3.78±0.64                                                         0.278   0.524   0.304--0.905    0.020[c](#tfn4-ol-07-05-1430){ref-type="table-fn"}
  Billirubin (mg/d)                    1.02±0.80                                                         0.219   1.163   0.758--1.785    0.490
  Prothrombin time (sec)               12.50±1.51                                                        0.083   1.159   0.985--1.365    0.076
  Creatinine (mg/dl)                   1.24±1.12                                                         0.111   1.171   0.942--1.456    0.155
  AST (U/l)                            39.5 (11-351)[b](#tfn3-ol-07-05-1430){ref-type="table-fn"}        0.002   1.004   1.000--1.009    0.073
  ALT (U/l)                            41.5 (9-371)[b](#tfn3-ol-07-05-1430){ref-type="table-fn"}         0.003   0.999   0.993\~1.005    0.692
  Alcohol use                          38 (37.3%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.332   1.387   0.723\~2.660    0.325
  Local recurrent time (month)         14 (0.07-194)[b](#tfn3-ol-07-05-1430){ref-type="table-fn"}        0.011   0.948   0.927--0.970    \<0.001[c](#tfn4-ol-07-05-1430){ref-type="table-fn"}
  Distal metastatic time (month)       34.5 (0.07--194)[b](#tfn3-ol-07-05-1430){ref-type="table-fn"}     0.010   0.934   0.915--0.953    \<0.001[c](#tfn4-ol-07-05-1430){ref-type="table-fn"}
  Disease free survival time (month)   14 (0.07--194)[b](#tfn3-ol-07-05-1430){ref-type="table-fn"}       0.011   0.948   0.927--0.969    \<0.001[c](#tfn4-ol-07-05-1430){ref-type="table-fn"}
  Major complex I subunit 6 defect     69 (67.6%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.371   1.326   0.641--2.742    0.446
  Major complex III subunit 3 defect   32 (31.4%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.352   0.950   0.477--1.893    0.885
  Major complex IV subunit 1 defect    51 (50.0%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.372   3.050   1.471\~6.324    0.003[c](#tfn4-ol-07-05-1430){ref-type="table-fn"}
  Major complex V subunit 6 defect     25 (24.5%)[a](#tfn2-ol-07-05-1430){ref-type="table-fn"}           0.361   1.255   0.618--2.546    0.530

Number (%);

median (range);

P\<0.05.

Data are presented as the mean ± standard deviation, unless stated otherwise. SE, standard error; HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotranferase; HCV, hepatitis C virus; major, immunohistochemical-negative area \>25%.

###### 

Multivariate analysis of parameters associated with overall survival time.

  Parameter                           SE      HR      95% CI          P-value
  ----------------------------------- ------- ------- --------------- ------------------------------------------------------
  Ascites                             0.500   1.697   0.637\~4.521    0.290
  Albumin, g/dl                       0.341   1.012   0.519\~1.975    0.971
  Local recurrent time, month         0.607   0.791   0.241\~2.598    0.699
  Distal metastatic time, month       0.017   0.924   0.894\~0.955    \<0.001[a](#tfn6-ol-07-05-1430){ref-type="table-fn"}
  Disease-free survival time, month   0.609   1.262   0.383\~4.159    0.702
  Major complex IV subunit 1 defect   0.474   5.676   2.243\~14.360   \<0.001[a](#tfn6-ol-07-05-1430){ref-type="table-fn"}

P\<0.05.

SE, standard error; HR, hazard ratio; CI, confidence interval; major, immunohistochemical-negative area \>25%.
